Awakening guardian angels: drugging the p53 pathway

Brown, Christopher J., Lain, Sonia, Verma, Chandra S., Fersht, Alan R., Lane, David P.·2009·Nature Reviews Cancer
DOI 10.1038/nrc2763

Cited by (914)

Items 101–200 of 914

  1. A Left‐Handed Solution to Peptide Inhibition of the p53–MDM2 Interaction
    Liu, Min, Pazgier, Marzena, Li, Changqing, Yuan, Weirong, Li, Chong, Lu, Wuyuan · 2010 · Angewandte Chemie International Edition
  2. p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
    Shyhmin Huang, Sergi Benavente, Eric A. Armstrong, Chunrong Li, Deric L. Wheeler, Paul M. Harari · 2011 · Cancer Research
  3. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
    Grazia Raffaella Tundo, Diego Sbardella, Anna Maria Santoro, Andrea Coletta, Francesco Oddone, Giuseppe Grasso, Danilo Milardi, Pedro Miguel Lacal, Stefano Marini, Roberto Purrello et al. · 2020 · Pharmacology & Therapeutics
  4. Molecular Rotors As Conditionally Fluorescent Labels for Rapid Detection of Biomolecular Interactions
    Walter L. Goh, Min Yen Lee, Thomas Leonard Joseph, Soo Tng Quah, Christopher John Brown, Chandra Shekhar Verma, Sydney Brenner, Farid John Ghadessy, Yin Nah Teo · 2014 · Journal of the American Chemical Society
  5. The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
    Anna Mandinova, Sam W. Lee · 2011 · Science Translational Medicine
  6. Targeting nucleocytoplasmic transport in cancer therapy
    Richard Hill, Bastien Cautain, Nuria de Pedro, Wolfgang Link · 2013 · Oncotarget
  7. Targeting p53 by small molecules in hematological malignancies
    Manujendra N. Saha, Lugui Qiu, Hong Hee Chang · 2013 · Journal of Hematology & Oncology
  8. The Role of Pontin and Reptin in Cellular Physiology and Cancer Etiology
    Yu-Qian Mao, Walid A. Houry · 2017 · Frontiers in Molecular Biosciences
  9. The aggregation of mutant p53 produces prion-like properties in cancer
    Luciana Pereira Rangel, Danielly C. Ferraz da Costa, Tuane C. R. G. Vieira, Jerson Lima Silva · 2014 · Prion
  10. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas
    Christine G. Joseph, Heejung Hwang, Yuchen Jiao, Laura DeLong Wood, Isaac Kinde, Jian Wu, Nils Mandahl, Jinyong Luo, Ralph H. Hruban, Luis Alberto Diaz et al. · 2013 · Genes Chromosomes and Cancer
  11. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact
    Giannis Mountzios, Theodoros N Rampias, Amanda K. Psyrri · 2014 · Annals of Oncology
  12. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies
    Jeffrey S. Ross, Laurie M. Gay, K. Wang, Jo‐Anne Vergilio, James H. Suh, Shakti H Ramkissoon, Hilary Somerset, Jennifer Maria Johnson, Jeffery Scott Russell, Siraj Mahamed Ali et al. · 2017 · Annals of Oncology
  13. Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression
    Min Deng, Long Zhang, Wenying Zheng, Jiale Chen, Nan Du, Meiqi Li, Weiqing Chen, Yonghong Huang, Ning Zeng, Yuanbin Song et al. · 2023 · Journal of Experimental & Clinical Cancer Research
  14. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53
    Qi Zhang, Shelya X. Zeng, Yu Zhang, Yi-Wei Zhang, Derong Ding, Qi-Zhuang Ye, Samy O. Meroueh, Hua Lu · 2012 · EMBO Molecular Medicine
  15. Genomic instability in mutant p53 cancer cells upon entotic engulfment
    Hannah L. Mackay, David Allan Moore, Callum Hall, Nicolai J. Birkbak, Mariam Jamal‐Hanjani, Saadia A. Karim, Vinaya M. Phatak, Lucia Piñon, Jennifer P. Morton, Charles Swanton et al. · 2018 · Nature Communications
  16. A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity
    Siqi Yan, Jin Yan, Dan Liu, Xiang Li, Qianyan Kang, Weiming You, Jinghua Zhang, Lei Wang, Zhiqi Tian, Wuyuan Lu et al. · 2021 · Theranostics
  17. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity
    Jiajia Zhou, Ilona Kryczek, Shasha Li, Li Xiong, Angelo Aguilar, Shuang Wei, Sara Grove, Linda Vatan, Jiali Yu, Yijian Yan et al. · 2021 · Nature Immunology
  18. Suppression of Host p53 Is Critical for Plasmodium Liver-Stage Infection
    Alexis Kaushansky, Albert S. Ye, Laura S. Austin, Sebastian A. Mikolajczak, Ashley M. Vaughan, Nelly M. Camargo, Peter G. Metzger, Alyse N. Douglass, Gavin MacBeath, Stefan H. I. Kappe · 2013 · Cell Reports
  19. Synthesis and applications of mirror-image proteins
    Harrison, Katriona, Mackay, Angus S., Kambanis, Lucas, Maxwell, Joshua W. C., Payne, Richard J. · 2023 · Nature Reviews Chemistry
  20. C16-ceramide is a natural regulatory ligand of p53 in cellular stress response
    Baharan Fekry, Kristen A. Jeffries, Amin Esmaeilniakooshkghazi, Zdzisław M. Szulc, Kevin J. Knagge, David R. Kirchner, David A. Horita, Sergey A. Krupenko, Natalia I. Krupenko · 2018 · Nature Communications
  21. Aberrant phase separation and cancer
    Kenzui Taniue, Nobuyoshi Akimitsu · 2021 · FEBS Journal
  22. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
    Shuai Wang, Fen‐Er Chen · 2022 · European Journal of Medicinal Chemistry
  23. Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations
    Asfar Sohail Azmi, Zhiwei Wang, Philip A. Philip, Ramzi M. Mohammad, Fazlul H. Sarkar · 2010 · Molecular Cancer Therapeutics
  24. Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents
    Karita Peltonen, Laureen C. Colis, Hester Liu, Sari Jäämaa, Henna M. Moore, Juulia Enbäck, Pirjo Maarit Laakkonen, Anne Vaahtokari, Richard John Jones, Taija M. af Hällström et al. · 2010 · PLoS ONE
  25. Targeting intrinsically disordered proteins in rational drug discovery
    Susmitha Ambadipudi, Markus Zweckstetter · 2015 · Expert Opinion on Drug Discovery
  26. p53 in neurodegenerative diseases and brain cancers
    Frédéric Checler, Cristine Alvès da Costa · 2013 · Pharmacology & Therapeutics
  27. The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant
    Burcu Anil, Christiane Riedinger, Jane Endicott, Martin E. M. Noble · 2013 · Acta Crystallographica Section D Biological Crystallography
  28. Multifunctional Bi2S3/PLGA nanocapsule for combined HIFU/radiation therapy
    Minghua Yao, Ming Ma, Yu Chen, Xiaoqing Jia, Guang Xu, Hui‐Xiong Xu, Hangrong Chen, RONG TSUN WU · 2014 · Biomaterials
  29. The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
    Daniel E. Johnson · 2014 · Endocrine Related Cancer
  30. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines
    Matthias G. J. Baud, Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger, Alan Roy Fersht · 2018 · European Journal of Medicinal Chemistry
  31. Potential of Bacillus subtilis lipopeptides in anti-cancer I: induction of apoptosis and paraptosis and inhibition of autophagy in K562 cells
    Haobin Zhao, Lu Yan, Xiaoguang Xu, Chunmei Jiang, Junling Shi, Yawen Zhang, Li Liu, Shuzhen Lei, Dongyan Shao, Qingsheng Huang · 2018 · AMB Express
  32. The p53 circuit board
    Kelly D. Sullivan, Corrie L. Gallant‐Behm, Ryan E. Henry, Jean-Luc Fraikin, Joaquin Maximiliano Espinosa · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  33. The p53 mRNA: an integral part of the cellular stress response
    Lucia Hároníková, Vanesa Olivares‐Illana, Lixiao Wang, Konstantinos Karakostis, Sa Chen, Robin Fåhræus · 2019 · Nucleic Acids Research
  34. Meiotic Recombination Provokes Functional Activation of the p53 Regulatory Network
    Wan-Jin Lu, Joseph A. Chapo, Ignasi Roig, John Abrams · 2010 · Science
  35. Discovery of small-molecule inhibitors of ubiquitin specific protease 7 (USP7) using integrated NMR and in silico techniques
    Di Lello, Paola, Pastor, Richard, Murray, Jeremy M., Blake, Robert A., Cohen, Frederick, Crawford, Terry D., Drobnick, Joy, Drummond, Jason, Kategaya, Lorna, Kleinheinz, Tracy et al. · 2017 · Journal of Medicinal Chemistry
  36. Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
    Zhuming Zhang, Xin‐Jie Chu, Jinjun Liu, Qingjie Ding, Jing Zhang, David Bartkovitz, Nan Jiang, Prabha Karnachi, Sung‐Sau So, Christian Tovar et al. · 2013 · ACS Medicinal Chemistry Letters
  37. Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
    Yujun Zhao, Denzil Bernard, Shaomeng Wang · 2013 · Biodiscovery
  38. Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress
    Karita Peltonen, Laureen C. Colis, Hester Liu, Sari Jäämaa, Zhewei Zhang, Taija af Hällström, Henna M. Moore, Paul Sirajuddin, Marikki Laiho · 2014 · Molecular Cancer Therapeutics
  39. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
    Ana Collazo-Lorduy, Mireia Castillo-Martín, Li Wang, Vaibhav G. Patel, Gopa Iyer, Emmet Jordan, Hikmat A Al‐Ahmadie, Issa Leonard, William K. Oh, Jun Zhu et al. · 2016 · European Urology
  40. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
    Marcus J.G.W. Ladds, Ingeborg M.M. van Leeuwen, Catherine J. Drummond, Su Chu, Alan R. Healy, Gergana Popova, Andrés Pastor Fernández, Tanzina Mollick, Suhas Deoram Darekar, Saikiran K. Sedimbi et al. · 2018 · Nature Communications
  41. Aberrant regulation of FBW7 in cancer
    Lixia Wang, Xiantao Ye, Yueyong Liu, Wenyi Wei, Zhiwei Peter Wang · 2014 · Oncotarget
  42. Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
    Alessia Bertamino, Maria Soprano, Simona Musella, Maria Rosaria Rusciano, Marina Sala, Ermelinda Vernieri, Veronica Di Sarno, Antonio Limatola, Alfonso Carotenuto, Sandro Cosconati et al. · 2013 · Journal of Medicinal Chemistry
  43. A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
    Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline et al. · 2015 · eLife
  44. Degradable polymeric nanocapsule for efficient intracellular delivery of a high molecular weight tumor-selective protein complex
    Muxun Zhao, Biliang Hu, Zhen Gu, Kye‐Il Joo, Pin Wang, Yi Tang · 2013 · Nano Today
  45. In Vitro Cytotoxicity and Adaptive Stress Responses to Selected Haloacetic Acid and Halobenzoquinone Water Disinfection Byproducts
    Erik Procházka, Beate Isabella Escher, Michael J. Plewa, Frédéric D.L. Leusch · 2015 · Chemical Research in Toxicology
  46. NFκB/p53 crosstalk—a promising new therapeutic target
    Schneider, Günter, Krämer, Oliver H. · 2011 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  47. Resveratrol prevents p53 aggregation in vitro and in breast cancer cells
    Danielly C. Ferraz da Costa, Nathali Campos, Ronimara A. Santos, Francisca Hildemagna Guedes-da-Silva, Mafalda Maria D.C. Martins-Dinis, Leticia Maria Zanphorlin, Carlos H.I. Ramos, Luciana Pereira Rangel, Jerson Lima Silva · 2018 · Oncotarget
  48. Recent developments in biological aspects of chalcones: the odyssey continues
    Anu Rani, Amit Ȧnand, Kewal Kumar, Vipan Kumar · 2019 · Expert Opinion on Drug Discovery
  49. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer
    Gabriella D’Orazi, Cinzia Rinaldo, Silvia Soddu · 2012 · Journal of Experimental & Clinical Cancer Research
  50. Oral squamous cell carcinoma: Key clinical questions, biomarker discovery, and the role of proteomics
    Uzma Urooj Malik, Shamshad Zarina, Stephen R. Pennington · 2015 · Archives of Oral Biology
  51. A Versatile Platform to Analyze Low-Affinity and Transient Protein-Protein Interactions in Living Cells in Real Time
    Yaocheng Li, Luo Wei Rodewald, Christian Hoppmann, Ee Tsin Wong, Sylvain Lebreton, Pavel Šafář, Marcel Pátek, Lei Wang, Kenneth F. Wertman, Geoffrey M. Wahl · 2014 · Cell Reports
  52. TP53 Genomic Status Regulates Sensitivity of Gastric Cancer Cells to the Histone Methylation Inhibitor 3-Deazaneplanocin A (DZNep)
    Lai Ling Cheng, Yoko Itahana, Zheng Deng Lei, Na‐Yu Chia, Yonghui Wu, Yingnan Yu, Shen Li Zhang, Aye Aye Thike, Anuradha Pandey, Steve Rozen et al. · 2012 · Clinical Cancer Research
  53. Targeting p53-MDM2-MDMX Loop for Cancer Therapy
    Qi Zhang, Shelya X. Zeng, Hua Lu · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
  54. In silico structure-based approaches to discover protein-protein interaction-targeting drugs
    Woong‐Hee Shin, Charles W. Christoffer, Daisuke Kihara · 2017 · Methods
  55. Molecularly targeted therapies for p53-mutant cancers
    Dekuang Zhao, William M. Tahaney, Abhijit Mazumdar, Michelle I. Savage, Powel H. Brown · 2017 · Cellular and Molecular Life Sciences
  56. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
    Lindi Chen, Raphaël F. Rousseau, Steven A. Middleton, GWEN L. NICHOLS, David R. Newell, John Lunec, Deborah A. Tweddle · 2015 · Oncotarget
  57. Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53–Mdm4
    Christian Hoppmann, Lei Wang · 2016 · Chemical Communications
  58. Role of p53 isoforms and aggregations in cancer
    SeJin Kim, Seong Soo A. An · 2016 · Medicine
  59. TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers
    Balázs Győrffy, Giulia Bottai, Jacqueline Lehmann‐Che, Gÿorgý Kéri, László Őrfi, Takayuki Iwamoto, Christine Desmedt, Giampaolo Bianchini, Nicholas C. Turner, Hugues de Thé et al. · 2014 · Molecular Oncology
  60. An Ultrahigh Affinity d -Peptide Antagonist Of MDM2
    Changyou Zhan, Le Zhao, Xiaoli Wei, Xueji Wu, Xishan Chen, Weirong Yuan, Weiyue Lu, Marzena Pazgier, Wuyuan Lu · 2012 · Journal of Medicinal Chemistry
  61. Reviving the guardian of the genome: Small molecule activators of p53
    Daniel Nguyen, Wenjuan Liao, Shelya X. Zeng, Hua Lu · 2017 · Pharmacology & Therapeutics
  62. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53–MDM2 Interaction in Colorectal Cancer
    Ziyuan Wang, Yueping Zhan, Jian Xu, Yang Wang, Mingyu Sun, Jia Chen, Tingyu Liang, Lili Wu, Ke Xu · 2020 · Journal of Agricultural and Food Chemistry
  63. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
    Sandrine Boyault, Youenn Drouet, Claudine Navarro, Thomas Bachelot, Christine Lasset, Isabelle Treilleux, Éric Tabone, Alain Puisieux, Qing Wang · 2011 · Breast Cancer Research and Treatment
  64. Evaluation of 122 advanced‐stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies
    Rami Nayef Al-Rohil, Ashley J. Tarasen, J. Andrew Carlson, Kai Wang, Adrienne Johnson, Roman Yelensky, Doron Lipson, Julia Andrea Elvin, Jo‐Anne Vergilio, Siraj Mahamed Ali et al. · 2015 · Cancer
  65. Resveratrol induces DNA damage in colon cancer cells by poisoning topoisomerase II and activates the ATM kinase to trigger p53-dependent apoptosis
    Benjamin Demoulin, Maryse Hermant, Cédric Castrogiovanni, Catherine Staudt, Patrick Dumont · 2015 · Toxicology in Vitro
  66. Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
    Chong Li, Marzena Pazgier, Jing Li, Changqing Li, Min Liu, Guozhang Zou, Zhenyu Li, Jiandong Chen, Sergey G. Tarasov, Weiyue Lu et al. · 2010 · Journal of Biological Chemistry
  67. Small-Molecule Inhibitors of the p53-MDM2 Interaction
    Binh Thanh Vu, Lyubomir T. Vassilev · 2010 · Current topics in microbiology and immunology
  68. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53–MDM2/MDMX Protein–Protein Interactions
    Peng Sang, Yan Shi, Junhao Lu, Lihong Chen, Leixiang Yang, Wade M. Borcherds, Sami Abdulkadir, Qi Li, Gary W. Daughdrill, Jiandong Chen et al. · 2020 · Journal of Medicinal Chemistry
  69. From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
    Lu Chen, John Kenneth Morrow, Hoang T. Tran, Sharangdhar S. Phatak, Lei Du‐Cuny, Shuxing Zhang · 2012 · Current Pharmaceutical Design
  70. EBV-Encoded miR-BART20-5p and miR-BART8 Inhibit the IFN-γ–STAT1 Pathway Associated with Disease Progression in Nasal NK-Cell Lymphoma
    Weiting Huang, Chung‐Wu Lin · 2014 · American Journal Of Pathology
  71. PP2A: The Wolf in Sheep’s Clothing?
    Maeve Bailey‐Whyte, Patrick Kiely · 2015 · Cancers
  72. Translational and clinical implications of the genetic landscape of prostate cancer
    Daniel Eidelberg Spratt, Zachary Stephan Zumsteg, Felix Yi-Chung Feng, Scott A. Tomlins · 2016 · Nature Reviews Clinical Oncology
  73. Development of selective small molecule MDM2 degraders based on nutlin
    Wang, Bo, Wu, Suzhen, Liu, Jin, Yang, Ka, Xie, Haibo, Tang, Weiping · 2019 · European Journal of Medicinal Chemistry
  74. A phosphorylation-dependent switch in the disordered p53 transactivation domain regulates DNA binding
    Xun Sun, H. Jane Dyson, Peter E. Wright · 2020 · Proceedings of the National Academy of Sciences
  75. Exosomes in the tumor microenvironment: Promoting cancer progression
    Ye Jin, Jianming Xing, Kejin Xu, Da Liu, Yue Zhuo · 2022 · Frontiers in Immunology
  76. Co-clustering phenome–genome for phenotype classification and disease gene discovery
    TaeHyun Hwang, Gowtham Atluri, Maoqiang Xie, Sanjoy Dey, Changjin Hong, Vipin Kumar, Rui Kuang · 2012 · Nucleic Acids Research
  77. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells
    Bower, Jacquelyn J., Vance, Leah D., Psioda, Matthew, Smith-Roe, Stephanie L., Simpson, Dennis A., Ibrahim, Joseph G., Hoadley, Katherine A., Perou, Charles M., Kaufmann, William K. · 2017 · npj Breast Cancer
  78. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
    Guangxia Chen, Shu Jie Zhang, Xiaohua He, Shiyu Liu, Chao Ma, Xiaoping Zou · 2014 · OncoTargets and Therapy
  79. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells
    Umamaheswari Natarajan, Thiagarajan Venkatesan, Vijayaraghavan Radhakrishnan, Shila Samuel, Appu Rathinavelu · 2018 · Cells
  80. Unnatural helical peptidic foldamers as protein segment mimics
    Peng Sang, Jianfeng Cai · 2023 · Chemical Society Reviews
  81. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
    Soňa Pecháčková, Kamila Burdová, Jan Benada, Petra Kleiblová, Gabriela Jeníková, Libor Macůrek · 2016 · Oncotarget
  82. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
    Deben, Christophe, Wouters, An, de Beeck, Ken Op, van Den Bossche, Jolien, Jacobs, Julie, Zwaenepoel, Karen, Peeters, Marc, Van Meerbeeck, Jan, Lardon, Filip, Rolfo, Christian et al. · 2015 · Oncotarget
  83. Autoantibodies against tumor-associated antigens in the early detection of lung cancer
    Liping Dai, Jun-Chieh James Tsay, Jitian Li, Ting-An Yie, John S. Munger, Harvey Ira Pass, William N. Rom, Yi Zhang, Eng M. Tan, Jian-Ying Zhang · 2016 · Lung Cancer
  84. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease
    Tommaso Cavalleri, Laura Angelici, Chiara Favero, Laura Dioni, Carolina Mensi, Claudia Bareggi, A. Palleschi, Arianna Rimessi, Dario Consonni, Lorenzo Bordini et al. · 2017 · PLoS ONE
  85. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents
    Amer M. Alanazi, Alaa A.‐M. Abdel‐Aziz, Ibrahim A. Al-Suwaidan, Sami G. Abdel‐Hamide, Taghreed Z. Shawer, Adel S. El‐Azab · 2014 · European Journal of Medicinal Chemistry
  86. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2
    Simon Vogel, Matthias R. Bauer, Andreas C. Joerger, Rainer Wilcken, Tobias Brandt, Dmitry B. Veprintsev, Trevor J. Rutherford, Alan Roy Fersht, Frank M. Boeckler · 2012 · Proceedings of the National Academy of Sciences
  87. Essential Roles of E3 Ubiquitin Ligases in p53 Regulation
    Sanam Sane, Khosrow S. Rezvani · 2017 · International Journal of Molecular Sciences
  88. Clinical implications of the molecular genetics of chronic lymphocytic leukemia
    Robin Foà, Ilaria Del Giudice, Anna Rita Guarini, Davide Rossi, Gianluca Gaïdano · 2013 · Haematologica
  89. Schedule-dependent interaction between anticancer treatments
    Sheng‐hong Chen, William C. Forrester, Galit Lahav · 2016 · Science
  90. Cell‐penetrating peptides: A tool for effective delivery in gene‐targeted therapies
    Inês Rego de Figueiredo, João Miguel Freire, Luis R. Flores, Ana Salomé Veiga, Miguel A. R. B. Castanho · 2014 · IUBMB Life
  91. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis
    Guocan Wang, Chia‐Hsin Chan, Yuan Gao, Hui‐Kuan Lin · 2011 · 癌症：英文版
  92. TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
    Thierry Soussi · 2011 · Advances in cancer research
  93. Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins
    Irene Lo Cigno, Federica Calati, Silvia Albertini, Marisa Gariglio · 2020 · Pathogens
  94. Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
    Tom Van Maerken, Ali Rihani, Daniel Dreidax, Sarah De Clercq, Nurten Yigit, Jean‐Christophe Marine, Frank Westermann, Anne De Paepe, Jo Vandesompele, Frank Speleman · 2011 · Molecular Cancer Therapeutics
  95. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy
    F. Niu, Jin Yan, Bohan Ma, Shichao Li, Yongping Shao, Pengcheng He, Wanggang Zhang, Wangxiao He, Peter X. Ma, Wuyuan Lu · 2018 · Biomaterials
  96. Beyond effector caspase inhibition
    Alexander H. Stegh, Ronald Anthony DePinho · 2011 · Cell Cycle
  97. Silver-Promoted Desilylation Catalyzed by Ortho- and Allosteric Cucurbiturils
    Xiaoyong Lu, Eric Masson · 2010 · Organic Letters
  98. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding
    Joel L. Kaar, Nicolas Basse, Andreas C. Joerger, Elaine Stephens, Trevor J. Rutherford, Alan Roy Fersht · 2010 · Protein Science
  99. Transcriptome analysis of tetraploid cells identifies cyclin D2 as a facilitator of adaptation to genome doubling in the presence of p53
    Tamara Potapova, Christopher W. Seidel, Andrew Box, Giulia Irene Rancati, Rong Li · 2016 · Molecular Biology of the Cell
  100. The p53-MDM2/MDMX axis – A chemotype perspective
    Kareem Khoury, Grzegorz M. Popowicz, Tad A. Holak, Alexander S. S. Dömling · 2011 · MedChemComm